Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients

Objective: Hemorrhagic and thromboembolic complications are common during support with extracorporeal membrane oxygenation (ECMO). As platelets play a pivotal role in hemostasis, we aimed to clarify how ECMO support affects platelet function.Methods: We included 33 adult patients undergoing ECMO sup...

Full description

Bibliographic Details
Main Authors: Camilla Mains Balle, Anni Nørgaard Jeppesen, Steffen Christensen, Anne-Mette Hvas
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fcvm.2019.00114/full
_version_ 1828414527130042368
author Camilla Mains Balle
Anni Nørgaard Jeppesen
Steffen Christensen
Anne-Mette Hvas
Anne-Mette Hvas
author_facet Camilla Mains Balle
Anni Nørgaard Jeppesen
Steffen Christensen
Anne-Mette Hvas
Anne-Mette Hvas
author_sort Camilla Mains Balle
collection DOAJ
description Objective: Hemorrhagic and thromboembolic complications are common during support with extracorporeal membrane oxygenation (ECMO). As platelets play a pivotal role in hemostasis, we aimed to clarify how ECMO support affects platelet function.Methods: We included 33 adult patients undergoing ECMO support at a tertiary ECMO referral center at Aarhus University Hospital, Denmark. Blood samples were collected on the first morning following ECMO initiation, and subsequently every morning until the 7th (±1) day. Platelet aggregation was evaluated by whole blood impedance aggregometry (Multiplate® Analyzer) using adenosine diphosphate (ADPtest), arachidonic acid (ASPItest), and thrombin-receptor-agonist-peptide-6 (TRAPtest) as agonists. A new model was applied, taking platelet count into consideration in interpretation of impedance aggregometry analyses. On the 1st and 3rd day, platelet activation was assessed by flow cytometry (Navios) using collagen-related peptide, ADP, TRAP, and arachidonic acid as agonists.Results: Blood samples from all 33 patients were analyzed on day 1 of ECMO support; 24 patients were still receiving ECMO and analyzed on day 3; 12 patients were analyzed on day 7 (±1). After ECMO initiation, platelet counts decreased significantly (p < 0.002) and remained low during ECMO support. ECMO patients demonstrated significantly reduced platelet aggregation on day 1 compared with healthy controls (all p < 0.001). However, when taking platelet count into consideration, platelet aggregation relative to platelet count did not differ from healthy controls. Flow cytometry analyses demonstrated impaired platelet activation in ECMO patients on day 1 compared with healthy controls (all p < 0.03). No substantial difference was found in platelet activation from day 1 to day 3 on ECMO support.Conclusions: Employing impedance aggregometry and flow cytometry, we found both impaired platelet aggregation and decreased platelet activation on day 1 of ECMO support compared with healthy controls. However, platelet aggregation was not impaired, when interpreted relative to the low platelet counts. Furthermore, levels of bound fibrinogen, on the surface of activated platelets in ECMO patients, were higher than in healthy controls. Together, these findings suggestively oppose that platelets are universally impaired during ECMO support. No marked difference in activation from day 1 to day 3 was seen during ECMO support.
first_indexed 2024-12-10T13:27:51Z
format Article
id doaj.art-6ba4bd619e294c3fbce178bc92bef2b6
institution Directory Open Access Journal
issn 2297-055X
language English
last_indexed 2024-12-10T13:27:51Z
publishDate 2019-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cardiovascular Medicine
spelling doaj.art-6ba4bd619e294c3fbce178bc92bef2b62022-12-22T01:47:06ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2019-08-01610.3389/fcvm.2019.00114469162Platelet Function During Extracorporeal Membrane Oxygenation in Adult PatientsCamilla Mains Balle0Anni Nørgaard Jeppesen1Steffen Christensen2Anne-Mette Hvas3Anne-Mette Hvas4Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, DenmarkDepartment of Anesthesiology and Intensive Care Medicine, Aarhus University Hospital, Aarhus, DenmarkDepartment of Anesthesiology and Intensive Care Medicine, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Medicine, Aarhus University, Aarhus, DenmarkObjective: Hemorrhagic and thromboembolic complications are common during support with extracorporeal membrane oxygenation (ECMO). As platelets play a pivotal role in hemostasis, we aimed to clarify how ECMO support affects platelet function.Methods: We included 33 adult patients undergoing ECMO support at a tertiary ECMO referral center at Aarhus University Hospital, Denmark. Blood samples were collected on the first morning following ECMO initiation, and subsequently every morning until the 7th (±1) day. Platelet aggregation was evaluated by whole blood impedance aggregometry (Multiplate® Analyzer) using adenosine diphosphate (ADPtest), arachidonic acid (ASPItest), and thrombin-receptor-agonist-peptide-6 (TRAPtest) as agonists. A new model was applied, taking platelet count into consideration in interpretation of impedance aggregometry analyses. On the 1st and 3rd day, platelet activation was assessed by flow cytometry (Navios) using collagen-related peptide, ADP, TRAP, and arachidonic acid as agonists.Results: Blood samples from all 33 patients were analyzed on day 1 of ECMO support; 24 patients were still receiving ECMO and analyzed on day 3; 12 patients were analyzed on day 7 (±1). After ECMO initiation, platelet counts decreased significantly (p < 0.002) and remained low during ECMO support. ECMO patients demonstrated significantly reduced platelet aggregation on day 1 compared with healthy controls (all p < 0.001). However, when taking platelet count into consideration, platelet aggregation relative to platelet count did not differ from healthy controls. Flow cytometry analyses demonstrated impaired platelet activation in ECMO patients on day 1 compared with healthy controls (all p < 0.03). No substantial difference was found in platelet activation from day 1 to day 3 on ECMO support.Conclusions: Employing impedance aggregometry and flow cytometry, we found both impaired platelet aggregation and decreased platelet activation on day 1 of ECMO support compared with healthy controls. However, platelet aggregation was not impaired, when interpreted relative to the low platelet counts. Furthermore, levels of bound fibrinogen, on the surface of activated platelets in ECMO patients, were higher than in healthy controls. Together, these findings suggestively oppose that platelets are universally impaired during ECMO support. No marked difference in activation from day 1 to day 3 was seen during ECMO support.https://www.frontiersin.org/article/10.3389/fcvm.2019.00114/fullblood plateletsextracorporeal membrane oxygenationextracorporeal life supportplatelet activationplatelet aggregationplatelet function tests
spellingShingle Camilla Mains Balle
Anni Nørgaard Jeppesen
Steffen Christensen
Anne-Mette Hvas
Anne-Mette Hvas
Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
Frontiers in Cardiovascular Medicine
blood platelets
extracorporeal membrane oxygenation
extracorporeal life support
platelet activation
platelet aggregation
platelet function tests
title Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
title_full Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
title_fullStr Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
title_full_unstemmed Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
title_short Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
title_sort platelet function during extracorporeal membrane oxygenation in adult patients
topic blood platelets
extracorporeal membrane oxygenation
extracorporeal life support
platelet activation
platelet aggregation
platelet function tests
url https://www.frontiersin.org/article/10.3389/fcvm.2019.00114/full
work_keys_str_mv AT camillamainsballe plateletfunctionduringextracorporealmembraneoxygenationinadultpatients
AT anninørgaardjeppesen plateletfunctionduringextracorporealmembraneoxygenationinadultpatients
AT steffenchristensen plateletfunctionduringextracorporealmembraneoxygenationinadultpatients
AT annemettehvas plateletfunctionduringextracorporealmembraneoxygenationinadultpatients
AT annemettehvas plateletfunctionduringextracorporealmembraneoxygenationinadultpatients